XOLAIR

@Novartis 2015  Direitos reservados  Proibida cópia ou reprodução sem prévia autorização 9. Referências Bibliográficas Barnes N., Menzies-Gow A., Mansur A.H., et al. Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-Wrold Study. Journal of Asthma, 2013; 50(5):529-536. Braman S.S. The Global Burden of Asthma. CHEST 2006; 130:4S–12S. Braunstahl G.J., Chen C.W., Maykut R., et. al. The eXpeRience registry: The ‘real-world’ effective- ness of omalizumab in allergic asthma. Respiratory Medicine (2013);107: 1141-1151. Brusselle G., Michils A., Louis R., et al. "Real-life" effectiveness of omalizumab in patients with se- vere persistent allergic asthma: The PERSIST study. Respir Med. 2009 Nov;103(11):1633-42. Bula do produto Xolair aprovada pela ANVISA em 11/04/2014 Cazzola M., Camiciottoli G., Bonavia M., et al. Italian real-life experience of omalizumab. Respir Med. 2010 Oct;104(10):1410-6. DATASUS. Informações de saúde, TABNET. Disponível em: http://www2.datasus.gov.br/DATASUS/index.php?area=0202. Acessado em: 10/10/2014. Fitzgerald JM, Ernst P, Field S et al. XCEED: Xolair* Canadian Evaluation of Effectiveness in asth- matic Disease. Poster #13; Presented at the 2008 CSACI Annual Scientific Meeting Hamilton, Ontario, Oc- tober 23 to 26, 2008. GINA. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Re- visado em 2014. Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med. 2005 Sep;99(9):1152-9. Hoskins G., McCowan C., Neville R.G., Thomas G.E., et al. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19–24. Korn S., Thielen A., Seyfried S., et al. Omalizumab in patients with severe persistent allergic asth- ma in a real-life setting in Germany. Respir Med. 2009 Nov;103(11):1725-31. Novak N. and Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003; 112(2): 252-262. Pace E, Ferraro M. et al. Clinical Benefits of 7 years of treatment with Omalizumab in severe un- controlled asthmatics Journal of Asthma (in Press). 2011;48(4):387-92. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40-47. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000 Nov;16(5):802-7.